Table 3 Principal characteristics and differences in the studied sample, depending on the existence and type of late gadolinium enhancement
No LGE | LGE | Chi square | No LGE | Focal MV | Linear MV | Diffuse | Kruskal Wallis | |
|---|---|---|---|---|---|---|---|---|
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |||
Male | 64 (52.5%) | 87 (65.4%) | 0.031 | 64 (52.5%) | 27 (77.1%) | 49 (59.0%) | 11 (73.3%) | 0.038 |
Female | 58 (47.5%) | 46 (34.6%) | 58 (47.5%) | 8 (22.9%) | 34 (41.0%) | 4 (26.7%) | ||
OK | 67 (54.9%) | 12 (9.0%) | <0.001 | 67 (54.9%) | 3 (8.6%) | 7 (8.4%) | 2 (13.3%) | <0.001 |
LVNC | 40 (32.8%) | 60 (45.1%) | 40 (32.8%) | 4 (11.4%) | 52 (62.7%) | 4 (26.7%) | ||
DCM | 4 (3.3%) | 23 (17.3%) | 4 (3.3%) | 3 (8.6%) | 18 (21.7%) | 2 (13.3%) | ||
HCM | 2 (1.6%) | 31 (23.3%) | 2 (1.6%) | 22 (62.9%) | 3 (3.6%) | 6 (40.0%) | ||
ARVD | 4 (3.3%) | 1 (0.8%) | 4 (3.3%) | 0 (0.0%) | 1 (1.2%) | 0 (0.0%) | ||
HHD | 4 (3.3%) | 2 (1.5%) | 4 (3.3%) | 0 (0.0%) | 2 (2.4%) | 0 (0.0%) | ||
MCD | 1 (0.8%) | 4 (3.0%) | 1 (0.8%) | 3 (8.6%) | 0 (0.0%) | 1 (6.7%) | ||
LVEF < 50% | 20 (16.4%) | 65 (48.9%) | <0.001 | 20 (16.4%) | 13 (37.1%) | 48 (57.8%) | 4 (26.7%) | <0.001 |
NC:C > 2.3:1 | 40 (32.8%) | 67 (50.4%) | 0.005 | 40 (32.8%) | 6 (17.1%) | 56 (67.5%) | 5 (33.3%) | <0.001 |
LVNC | 40 (32.8%) | 60 (45.1%) | <0.001 | 40 (32.8%) | 4 (11.4%) | 52 (63.9%) | 4 (26.7%) | <0.001 |
MNC | 27 (32.9%) | 29 (39.7%) | 0.410 | 27 (32.9%) | 10 (32.3%) | 14 (45.2%) | 5 (45.5%) | 0.560 |
MCE | 26 (21.3%) | 59 (44.4%) | <0.001 | 26 (21.3%) | 17 (48.6%) | 33 (39.8%) | 9 (60.0%) | 0.001 |
NC > 20%LV | 39 (32.0%) | 59 (44.4%) | 0.047 | 39 (32.0%) | 3 (8.6%) | 52 (62.7%) | 4 (26.7%) | <0.001 |